Opinion|Videos|May 21, 2025
CABINET Trial: Study Design and Patient Population
Author(s)Thorvardur R. Halfdanarson, MD
A panelist discusses how the CABINET trial was a National Cancer Institute (NCI)–supported study conducted by the Alliance for Clinical Trials in Oncology that enrolled patients with well-differentiated grade 1 through 3 pancreatic or extrapancreatic neuroendocrine tumors who had progressed after somatostatin analogue therapy and at least 1 other FDA-approved therapy.
Advertisement
Video content above is prompted by the following:
The CABINET Trial Design and Significance
Key Themes:
- Trial Design:
- NCI-supported study run through the Alliance for Clinical Trials in Oncology network
- Included well-differentiated grade 1, 2, or 3 pancreatic or extrapancreatic neuroendocrine tumors
- Required disease progression after somatostatin analogue therapy and at least 1 other FDA-approved therapy
- 2:1 randomization to cabozantinib vs placebo with crossover option
- Trial Significance:
- Rigorously conducted through academic institutions and large community practices
- Particularly important for demonstrating active therapy post radioligand therapy
- Protocol modifications improved accrual rates as the trial progressed
Notable Insights:
Dr Halfdanarson emphasized that the CABINET trial provides valuable evidence for treatment options following radioligand therapy with lutetium-177 dotatate, addressing a knowledge gap in the field.
Advertisement
Related to this article
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
2
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
5